Trial Profile

Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olmesartan medoxomil (Primary) ; Amlodipine
Indications Essential hypertension
Focus Biomarker; Therapeutic Use
Acronyms VAMOS
Sponsors Daiichi Sankyo Europe

Most Recent Events

29 Apr 2012 Secondary endpoint results presented at the 22nd European Meeting on Hypertension.
28 Apr 2012 Planned number of patients changed from 60 to 70 as reported by European Clinical Trials Database record.
28 Apr 2012 New source identified and integrated (European Clinical Trials Database record).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com